CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 +2 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07359924
NCT07359924Phase 2Completed

Application of Liquid Fraction of Platelet-rich Fibrin in Face Care Cream.

Poznan University of Medical Sciences·interventional·Posted Jan 22, 2026·Updated Jan 22, 2026

In Brief

A Phase 2 clinical trial evaluating The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20, The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGF, and 1 other intervention for Skin Ageing. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The study evaluates the effectiveness of cosmetic preparations containing PRF, conducted through in vivo studies. Material and Methods: The study involved 20 healthy volunteers (aged 20-40) who received three identically packaged creams to be applied to specific facial areas. Formulation 1: base formulation (control), Formulation 2: base formulation with human epidermal growth factor (EGF), and Formulation 3: base formulation with platelet-rich fibrin (PRF). Volunteers applied the creams as directed for a period of four weeks. Skin assessments was conducted at baseline (week 0), and at weeks 1, 2, and 4. Trans-epidermal Water Loss (TEWL), skin hydration using corneometry to determine the moisture content of the stratum corneum, skin elasticity using a cutometer to measure the skin's ability to return to its original state after deformation, and dermal bioavailability were measured. EGF concentration in the stratum corneum will be measured using the tape-stripping method followed by HPLC (High-Performance Liquid Chroma-tography) analysis. Results: A significant decrease in TEWL was observed in formulations 2 and 3, indicating improved skin barrier function. Formulation 3 showed the highest increase in skin hy-dration, followed by formulation 2. Both formulations 2 and 3 demonstrated improvements in skin elasticity, with formulation 3 showing the greatest enhancement. EGF concentration in the stratum corneum increased over the four-week period, reaching equilibrium with the product concentration by week four. Con-clusion: The in vivo instrumental compatibility studies confirmed that the new cosmetic formulations containing EGF and PRF are safe and effective for human skin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Ageing
CountriesPoland
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJan 22, 2026
Enrollment StartFeb 3, 2022
Primary CompletionAug 8, 2022
Study CompletionFeb 6, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5 months ago

Interventions

The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20combination

Daily skin application for the following 4 weeks at the same place according to the instruction

The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGFcombination

Daily skin application for the following 4 weeks at the same place according to the instruction

The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRFbiological

Daily skin application for the following 4 weeks at the same place according to the instruction